July 1, 2021

Exacis Biotherapeutics Makes Strategic Investment in Manufacturing by Hiring Head of Technical Operations and Securing Space in a GMP Cleanroom Facility Recently Completed by Factor Bioscience

Exacis Biotherapeutics Bryan Jones PhD brings significant experience to role of Head of Technical Operations Cleanroom facility gives Exacis capacity to produce mRNA-based cell therapies […]
March 26, 2021

Exacis Biotherapeutics Develops mRNA-Engineered iPSC-Derived NK Cells for Difficult-To-Treat Tumors

Exacis Biotherapeutics Exacis has generated NK cells from iPSCs engineered using mRNA gene-editing technology to resist rejection by the patient’s immune system ExaNK™ cells show […]
January 29, 2021

Exacis Biotherapeutics Announces Key Addition to its Executive Leadership Team with Dirk Huebner MD Joining as Chief Medical Officer

Exacis Biotherapeutics Names key executive Dirk Huebner MD, as Chief Medical Officer Immuno-oncology cell therapy company creates innovative, stealth and performance engineered T and NK […]
January 6, 2021

Exacis Biotherapeutics Announces Its Launch and mRNA Technology In-Licensing for Targeted CAR-NK and CAR-T Cell Cancer Therapies

Exacis Biotherapeutics Focuses on immuno-oncology Creates innovative, engineered T and NK cells from induced pluripotent stem cells (iPSC) In-licenses mRNA technologies developed by Factor Bioscience […]